In Situ Biomineralization Enhances Mitochondrial Transplantation to Differentiating Osteoclast Precursors for Suppressing Cancer-Induced Osteolysis 

Yu Zhang et al.

Research (Wash D C). 2026 Aug 19;9:1410. doi: 10.34133/research.1410. eCollection 2026.

Published on August 20, 2026

Abstract

ABSTRACT

Cancer-induced bone osteolysis is a common complication of multiple malignancies and may actively contribute to bone metastasis. Its core pathology is closely associated with mitochondrial metabolic dysfunction during osteoclast differentiation. In this study, a mitochondrial transplantation strategy based on in situ biomineralization (Mito@ZIF@RGD) was developed to overcome multiple delivery barriers in differentiating osteoclast precursor cells. A zeolitic imidazolate framework-8 (ZIF-8) shell was formed via the in situ self-assembly of Zn2+ and 2-methylimidazole on the mitochondrial membrane, thereby enhancing mitochondrial stability. Meanwhile, cyclic RGD (arginine-glycine-aspartic acid) peptides were coordinated with exposed Zn2+ sites on the outer shell to promote αvβ3-mediated uptake during osteoclast differentiation. Furthermore, the sustained Zn2+ release from the ZIF-8 biomineralization reshaped intracellular ionic homeostasis, thereby improving the durability of therapeutic efficacy following mitochondrial transplantation. In vitro experiments demonstrated that ZIF-8 encapsulation stabilized mitochondria and enabled sustained adenosine triphosphate production for more than 48 h. RGD modification improved cellular uptake efficiency by approximately 55% in differentiating osteoclast precursors, while the mildly acidic microenvironment triggered the coordinated release of mitochondria and Zn2+, effectively reducing intracellular reactive oxygen species levels and osteoclast formation. In vivo, Mito@ZIF@RGD treatment promoted the recovery of bone mineral density, suppressed osteoclast surface area formation by approximately 30%, and preserved bone microstructural integrity. Therefore, as a stable, specific, and durable mitochondrial transplantation platform modulating cellular metabolism during osteoclast differentiation, Mito@ZIF@RGD represents a stable and promising platform for the treatment of cancer-induced osteolysis and other metabolic imbalance-associated bone diseases.

PMID:42620699 | PMC:PMC13486730 | DOI:10.34133/research.1410

 Read More

← Back to Publications
Mikkola Lea et al.Biochem Biophys Rep. 2026 Nov 9;48:102875. doi: 10.1016/j.bbrep.2026.102875. eCollection 2026 Dec.
Gautier Follain et al.Bio Protoc. 2026 Nov 5;16(21):e5861. doi: 10.21769/BioProtoc.5861. eCollection 2026 Nov 5.
Francesca Bottanelli et al.J Cell Sci. 2026 Nov 1;139(21):jcs265433. doi: 10.1242/jcs.265433. Epub 2026 Nov 12.
Aliaa E Ali et al.Hum Mutat. 2026 Nov 8;2026:8234670. doi: 10.1155/humu/8234670. eCollection 2026.
Marie Christine Goess et al.J Crohns Colitis. 2026 Nov 7;20(11):jjag182. doi: 10.1093/ecco-jcc/jjag182.